Edgar Filing: ABBOTT LABORATORIES - Form 8-K

ABBOTT LABORATORIES Form 8-K August 03, 2007

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SE	CURITIES AND EXCE	IANGE COMMISSION	JN
WAS	SHINGTON, D.C. 20549		
FC	ORM 8-K		
Purs	RRENT REPORT suant to Section 13 or 15(d) of the urities Exchange Act of 1934		
	31, 2007 of Report (Date of earliest event reported)		
AE	BBOTT LABORATORI	ES	
(Exac	et name of registrant as specified in its charter)		
(State	Illinois e or other Jurisdiction of Incorporation)	1-2189 (Commission File Number)	36-0698440 (I.R.S. Employer Identification No.)
Abbo	Abbott Park Road ott Park, Illinois 60064-6400 dress of principal executive offices)(Zip	o Code)	
	Registrant s to	elephone number, including area code: (84	7) 937-6100
	k the appropriate box if the Form 8-K filing bllowing provisions:	is intended to simultaneously satisfy the	filing obligation of the registrant under any of
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
o 240.	Pre-commencement communication 14d-2(b))	ns pursuant to Rule 14d-2(b) under	the Exchange Act (17 CFR
o 240.	Pre-commencement communication 13e-4(c))	ns pursuant to Rule 13e-4(c) under	the Exchange Act (17 CFR

## Edgar Filing: ABBOTT LABORATORIES - Form 8-K

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Abbott today announced that Richard A. Gonzalez, President and Chief Operating Officer and a member of Abbott s Board of Directors, plans to retire from the company after 30 years of service, effective September 30, 2007.

Accordingly, Abbott s medical devices, pharmaceuticals, nutritionals and diagnostics businesses will report directly to Miles D. White, Chairman and Chief Executive Officer.

## **Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Abbott Laboratories** 

Date: August 3, 2007

By: /s/ Thomas C. Freyman

Thomas C. Freyman

Executive Vice President, Finance and Chief Financial Officer